Anti B7-H3 antibody

1. An antibody characterized by having the following properties:

(a) specific binding to an IgC1 and/or IgC2 domain of B7-H3,

(b) having a constant region that is a human constant region;

(c) comprising CDRH1 consisting of an amino acid sequence comprising SEQ ID NO: 92, CDRH2 consisting of an amino acid sequence comprising SEQ ID NO: 93, and CDRH3 consisting of an amino acid sequence comprising SEQ ID NO: 94 as complementarity determining regions of the heavy chain and comprising CDRL1 consisting of an amino acid sequence comprising SEQ ID NO: 95, CDRL2 consisting of an amino acid sequence comprising SEQ ID NO: 96, and CDRL3 consisting of an amino acid sequence comprising SEQ ID NO: 97 as complementarity determining regions of the light chain;

(d) having an antibody-dependent cell-mediated phagocytosis (ADCP) activity; and

(e) having an in vivo antitumor activity against tumors expressing B7-H3 comprising SEQ ID NO: 6 or SEQ ID NO:10.

2. The antibody according to claim 1 , which has a competitive inhibitory activity against M30 antibody for the binding to B7-H3.

3. The antibody according to claim 1 , which has an antibody-dependent cellular cytotoxicity (ADCC) activity and/or a complement-dependent cytotoxicity (CDC) activity.

4. The antibody according to any one of claims 1 , 2 and 3 , wherein the tumor is cancer.

5. The antibody according to claim 4 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

6. The antibody according to claim 1 , which comprises a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 51 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 23 to 130 in SEQ ID NO: 53.

7. The antibody according to claim 1 , which comprises a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 63 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 59.

8. The antibody according to claim 1 , which is humanized.

9. The antibody according to claim 8 , which comprises a heavy chain variable region consisting of an amino acid sequence selected from the group consisting of (a) an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85, (b) an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 87, (c) an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 89, (d) an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 91, (e) an amino acid sequence having a homology of at least 95% or more with any of the framework amino acid residues of the sequences (a) to (d), and (f) an amino acid sequence wherein one or several amino acids are deleted, substituted or added within any of the framework region sequences of (a) to (d); and a light chain variable region consisting of an amino acid sequence selected from the group consisting of (g) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 71, (h) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 73, (i) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 75, (j) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 77, (k) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 79, (l) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 81, (m) an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 83, (n) an amino acid sequence having a homology of at least 95% or more with any of the framework amino acids of the sequences (g) to (m), and (o) an amino acid sequence wherein one or several amino acids are deleted, substituted or added within any of the framework region sequences of (g) to (m).

10. The antibody according to claim 9 , which comprises a heavy chain variable region and a light chain variable region selected from the group consisting of a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 71; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 73; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 75; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 77; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 79; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 81; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 85 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO:83; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 91 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 71; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 91 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 73; a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO:91 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 75; and a heavy chain variable region consisting of an amino acid sequence comprising amino acid numbers 20 to 141 in SEQ ID NO: 91 and a light chain variable region consisting of an amino acid sequence comprising amino acid numbers 21 to 128 in SEQ ID NO: 77.

11. The antibody according to claim 9 , which comprises a heavy chain and a light chain selected from the group consisting of a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 71; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 73; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 75; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 77; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 79; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 81; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 83; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 71; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 73; a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 75; and a heavy chain consisting of an amino acid sequence comprising amino acid numbers 20 to 471 in SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising amino acid numbers 21 to 233 in SEQ ID NO: 77.

12. The antibody according to claim 9 , which comprises a heavy chain and a light chain selected from the group consisting of: a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 71; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 73; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 75; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 77; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO:85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 79; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 81; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 85 and a light chain consisting of an amino acid sequence SEQ ID NO: 83; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising SEQ ID NO:71; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 73; a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 75; and a heavy chain consisting of an amino acid sequence comprising SEQ ID NO: 91 and a light chain consisting of an amino acid sequence comprising SEQ ID NO: 77.

13. A polynucleotide encoding the antibody according to claim 1 .

14. The polynucleotide according to claim 13 , which comprises a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 50 and a nucleotide sequence comprising nucleotide numbers 67 to 390 in SEQ ID NO:52.

15. The polynucleotide according to claim 13 , which comprises a nucleotide sequence comprising SEQ ID NO: 62 and a nucleotide sequence comprising SEQ ID NO: 58.

16. The polynucleotide according to claim 13 , which comprises: a nucleotide sequence selected from the group consisting of (a) a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84, (b) a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 86, (c) a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 88, (d) a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 90, and (e) a nucleotide sequence comprising a polynucleotide which hybridizes to a polynucleotide consisting of a nucleotide sequence complementary to any of the nucleotide sequences (a) to (d) under stringent conditions; and a nucleotide sequence selected from the group consisting of (f) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 70, (g) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 72, (h) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 74, (i) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 76, (j) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 78, (k) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 80, (l) a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 82, and (m) a nucleotide sequence comprising a polynucleotide which hybridizes to a polynucleotide consisting of a nucleotide sequence complementary to any of the nucleotide sequences (f) to (l) under stringent conditions.

17. The polynucleotide according to claim 16 , which comprises nucleotide sequences selected from the group consisting of: a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 70; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 72; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 74; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 76; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 78; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 80; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 82; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 70; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 72; a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 74; and a nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO: 76.

18. The polynucleotide according to claim 16 , which comprises nucleotide sequences selected from the group consisting of: a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 70; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 72; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 74; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 76; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 78; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 80; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 84 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 82; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 70; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 72; a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 74; and a nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ ID NO: 90 and a nucleotide sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO: 76.

19. The polynucleotide according to claim 13 , which comprises nucleotide sequences selected from the group consisting of: a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 70; a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 72; a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 74; a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 76; a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 78; a nucleotide sequence comprising SEQ ID NO:84 and a nucleotide sequence comprising SEQ ID NO: 80; a nucleotide sequence comprising SEQ ID NO: 84 and a nucleotide sequence comprising SEQ ID NO: 82; a nucleotide sequence comprising SEQ ID NO: 90 and a nucleotide sequence comprising SEQ ID NO: 70; a nucleotide sequence comprising SEQ ID NO: 90 and a nucleotide sequence comprising SEQ ID NO: 72; a nucleotide sequence comprising SEQ ID NO: 90 and a nucleotide sequence comprising SEQ ID NO: 74; and a nucleotide sequence comprising SEQ ID NO: 90 and a nucleotide sequence comprising SEQ ID NO: 76.

20. An expression vector comprising a polynucleotide according to any one of claims 13 - 19 .

21. A host cell, which is transformed in vitro with the expression vector according to claim 20 .

22. The host cell according to claim 21 , wherein the host cell is a eukaryotic cell.

23. A method of producing an antibody, comprising a step of culturing a host cell according to claim 21 and a step of collecting the antibody from a cultured product obtained in the culturing step.

24. An antibody obtained by a production method comprising a step of culturing a host cell according to claim 21 and a step of collecting the antibody from a cultured product obtained in the culturing step.

25. The antibody according to any one of claims 1 , 2 , 3 , 6 and 7 - 12 , wherein the modification of a glycan, when present, is regulated to enhance an antibody-dependent cellular cytotoxic activity as compared with an unmodified antibody or functional fragment of the antibody.

26. A pharmaceutical composition, comprising at least one of the antibodies according to any one of claims 1 , 2 , 3 , 10 and 7 - 12 .

27. A method of treating a tumor expressing B7-H3, comprising administering at least one of the antibodies according to any one of claims, 1 , 2 , 3 , 6 and 7 - 12 to an individual.

28. A method of treating a tumor expressing B7-H3, comprising administering at least one of the antibodies according to any one of claims, 1 , 2 , 3 , 6 and 7 - 12 and at least one therapeutic agent for cancer simultaneously, separately, or sequentially to an individual.

29. The method according to claim 27 , wherein the tumor is cancer.

30. The method according to claim 29 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

31. The method according to claim 28 , wherein the tumor is cancer.

32. The method according to claim 31 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

33. An antibody obtained by a production method comprising a step of culturing a host cell transformed with an expression vector comprising a polynucleotide encoding the antibody according to claim 4 and a step of collecting the antibody from a cultured product obtained in the culturing step.

34. The antibody according to claim 33 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

35. The antibody of claim 24 , wherein the modification of a glycan, when present, is regulated to enhance an antibody-dependent cellular cytotoxic activity as compared with an unmodified antibody.

36. The antibody according to claim 4 , wherein the modification of a glycan, when present, is regulated to enhance an antibody dependent cellular cytotoxicity as compared with an unmodified antibody.

37. The antibody according to claim 36 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

38. An antibody according to claim 33 , wherein the modification of a glycan, when present, is regulated to enhance an antibody dependent cellular cytotoxicity as compared with an unmodified antibody.

39. An antibody according to claim 34 , wherein the modification of a glycan, when present, is regulated to enhance an antibody dependent cellular cytotoxicity as compared with an unmodified antibody.

40. A pharmaceutical composition, comprising at least one antibody according to claim 24 .

41. A pharmaceutical composition, comprising at least one antibody according to claim 25 .

42. A pharmaceutical composition, comprising at least one antibody according to claim 33 .

43. A pharmaceutical composition, comprising at least one antibody according to claim 4 .

44. The pharmaceutical composition according to claim 43 , wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer.

45. A pharmaceutical composition, comprising at least one antibody according to claim 34 .

46. A pharmaceutical composition, comprising at least one antibody according to claim 35 .

47. A pharmaceutical composition, comprising at least one antibody according to claim 36 .

48. A pharmaceutical composition, comprising at least one antibody according to claim 37 .

49. A pharmaceutical composition, comprising at least one antibody according to claim 38 .

50. A pharmaceutical composition, comprising at least one antibody according to claim 39 .

51. A method of treating a tumor expressing B7-H3, comprising administering at least one of the antibodies according to claim 24 to an individual.

52. A method of treating a tumor expressing B7-H3, comprising administering at least one of the antibodies according to claim 24 and at least one therapeutic agent for cancer simultaneously, separately, or sequentially to an individual.